The active implantable medical devices market accounted to US$ 39,026.9 Mn in 2017 and is expected to grow at a CAGR of 7.9% during the forecast period 2018 - 2025, to account to US$ 22,096.9 Mn by 2025.
Europe is was the second largest geographic market and it is expected to be the second highest revenue contributor throughout the forecast period. Europe market is driven by the factors such as frequent product launches and increasing awareness among the population in the region. Additionally, rising chronic conditions and increasing government initiatives for healthcare are some major factors have that influence the European active implantable medical devices market.
Technological Advancements and New Product Launches
The active implantable medical devices is an emerging field in the medical industry and has led to various developments of the products, in the field of cardiology, neurology and otology. Many of the market players are developing novel products in order to minimize the burden of cardiovascular diseases, neurological disorders and hearing disorders. For instance, Boston Scientific Corporation in September 2017, launched the Resonate family of Implantable Cardioverter Defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. This product is powered by EnduraLife battery technology, which has double battery capacity as compared to other devices. Thus increasing the longevity of devices and managing heart failure more efficiently.
Increasing Burden of Cardiovascular Diseases, Neurological Disorders and Hearing Disorders
Active implantable devices like pacemakers, cochlear implants, ventricular assist devices, spinal cord stimulators and others are used to treat cardiovascular diseases, neurological disorders and hearing disorders. Thus the increasing prevalence of cardiovascular diseases, neurological disorders and hearing disorders is expected to drive market growth during the forecast period. According to the World health organization in 2017, cardiovascular diseases are number 1 cause of death all over the world. It also mentioned that in 2016, 17.9 million people across the globe died due to cardiovascular diseases.
The global active implantable medical devices market by product was led by implantable cardioverter defibrillators. In 2017, the implantable cardioverter defibrillators held a largest market share of 30.9% of the active implantable medical devices market, by product. The implantable cardioverter defibrillators segment is expected to dominate the market in 2025 owing to the rising prevalence of arrhythmia, enhances the growth of implantable cardioverter defibrillators. Atrial fibrillation (AF) is the most common type arrhythmia observed among the population, which may further lead to stroke, heart failure and other heart-related complications. This segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2025.
End User Insights
The active implantable medical devices market by end user is segmented into hospitals, ambulatory surgery centers and specialty clinics. The hospitals segment is anticipated to grow at a CAGR of 8.1% during the forecast period. The increasing adoption of new technology devices in the hospitals and rising hospital research drives the market growth.
Approvals and agreements were observed as the most adopted strategy in global active implantable medical devices industry. Few of the recent product launch and collaboration and others are listed below;
2018: In August, 2018, Abbott received FDA approval for software upgrade for its Infinity implants used to treat Parkinson’s and essential tremor full-body MRI compatibility.
2017: In November, 2017, Medtronic received CE (Conformité Européenne) Mark for the world's smallest fully implantable spinal cord stimulator. The neurostimulator is placed under patient’s skin in order to deliver mild electrical impulses through a lead implanted in the epidural space, which act to block pain signals from going to the brain.
2016: In November 2016, BIOTRONIK today announced the launch of Inventra HF-T, implantable cardioverter defibrillator (ICD) that delivers an ultra-high energy with 42 joules (J) on the first shock. Thus providing technologically advanced products that improve patient lives.
ACTIVE IMPLANTABLE MEDICAL DEVICES – MARKET SEGMENTATION
By End User
TABLE OF CONTENTS1. INTRODUCTION 19
LIST OF TABLESTABLE 1. NORTH AMERICA ACTIVE IMPLANTABLE MEDICAL DEVICES MARKET REVENUE AND FORECASTS TO 2025, BY PRODUCT (US$ MN) 57
LIST OF FIGURESFIGURE 1. ASIA PACIFIC ACTIVE IMPLANTABLE MEDICAL DEVICES MARKET, REVENUE (US$ MN), BY GEOGRAPHY 2017 & 2025 20
The List of Companies - Active Implantable Medical Devices Market
3. Cochlear Ltd.
4. Boston Scientific Corporation
8. William Demant Holding A/S
9. LivaNova PLC
10. Nurotron Biotechnology Co. Ltd.